Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Jain

Showing results (351-360 of 420) with videos related to

Pageof 42
Sort By:
Blood Advances|September 3, 2020
Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphomaHamza Hashmi, Abu-Sayeef Mirza, Alicia Darwin, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 30, 2022
Performance of Xpert<sup>®</sup> MTB/RIF and Xpert<sup>®</sup> Ultra for the diagnosis of tuberculous meningitis in childrenN N Pradhan, M S Paradkar, A Kagal, et al.
Science (New York, N.Y.)|March 29, 2018
Translocation of a gut pathobiont drives autoimmunity in mice and humansS Manfredo Vieira, M Hiltensperger, V Kumar, et al.
Cancer Immunology Research|April 11, 2023
Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell TherapyKai Rejeski, David M Cordas Dos Santos, Nathan H Parker, et al.
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.
Journal of Hematology & Oncology|July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myelomaKai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.
The Journal of Clinical Investigation|October 30, 2025
IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapyPayal Goala, Yongliang Zhang, Nolan Beatty, et al.
Pageof 42

Showing results (351-360 of 420) with videos related to

Sort By:
Pageof 42
Blood Advances|September 3, 2020
Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphomaHamza Hashmi, Abu-Sayeef Mirza, Alicia Darwin, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 30, 2022
Performance of Xpert<sup>®</sup> MTB/RIF and Xpert<sup>®</sup> Ultra for the diagnosis of tuberculous meningitis in childrenN N Pradhan, M S Paradkar, A Kagal, et al.
Science (New York, N.Y.)|March 29, 2018
Translocation of a gut pathobiont drives autoimmunity in mice and humansS Manfredo Vieira, M Hiltensperger, V Kumar, et al.
Cancer Immunology Research|April 11, 2023
Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell TherapyKai Rejeski, David M Cordas Dos Santos, Nathan H Parker, et al.
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.
Journal of Hematology & Oncology|July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myelomaKai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Blood Advances|July 24, 2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaErin A Dean, Rahul S Mhaskar, Hong Lu, et al.
The Journal of Clinical Investigation|October 30, 2025
IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapyPayal Goala, Yongliang Zhang, Nolan Beatty, et al.
Pageof 42